ReadYourDNA

Mirabegron (Myrbetriq)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Mirabegron

What it is

Mirabegron is a beta-3 adrenergic agonist: it relaxes the bladder muscle during filling, so the bladder holds more urine. It is used for overactive bladder, with urgency, frequent urination and leakage, and in children for a bladder problem caused by nerve damage. It is sold as Myrbetriq and Betmiga.

How genes come into it

Mirabegron is cleared by several routes, including the liver enzymes CYP3A4 and CYP2D6. People with no working CYP2D6 copies (poor metabolizers) have modestly higher levels, which the US FDA lists as an effect on drug levels; mirabegron also blocks CYP2D6 itself. There is no CPIC or DPWG guideline, and the few other studies on this page are single findings.

Published guidelines

Clinical guidelines that name a gene for Mirabegron. They sort people into groups by the gene copies they carry.

US FDA: CYP2D6. CYP2D6 activity score 0. Data that Demonstrate a Potential Impact on Pharmacokinetic Properties Only.

What research found

Every published finding on gene variants and Mirabegron. Upload your DNA file to see which of these rows apply to you.

Metabolism (6 findings)

Studies of how quickly the body processes this medication.

CYP2D6 CYP2D6 intermediate metabolizer: CYP2D6 intermediate metabolizer is associated with increased half-life time of mirabegron in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.

SLC19A1 rs1051266: Genotype TT is associated with decreased dose-adjusted trough concentrations of mirabegron in healthy individuals as compared to genotype CT.

SLC6A2 rs12708954: Genotype CC is associated with increased clearance of mirabegron in healthy individuals as compared to genotype AC.

UGT1A3 rs2008584: Genotype AA is associated with decreased half-life time of mirabegron in healthy individuals as compared to genotype AG.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Aciphex (PPIs)

Advair (Corticosteroid + LABA)

AeroBid (Corticosteroids)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com